Products
Pre-made Cabiralizumab benchmark antibody ( Whole mAb, anti-CSF1R therapeutic antibody, Anti-FMS/CSFR/FIM2/HDLS/C-FMS/CD115/HDLS1/CSF-1R/BANDDOS/M-CSF-R Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-087
Pre-Made Cabiralizumab biosimilar, Whole mAb, Anti-CSF1R Antibody: Anti-FMS/CSFR/FIM2/HDLS/C-FMS/CD115/HDLS1/CSF-1R/BANDDOS/M-CSF-R therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Cabiralizumab is developed as a monoclonal antibody antagonist targeted CSF1R, with potential antineoplastic activity. Upon administration, the drug inhibits the binding of CSF1R to CSF1 and interleukin-34 (IL-34) via binding to CSF1R expressed on monocytes, macrophages, and osteoclasts competitively.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-087-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size： 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Cabiralizumab biosimilar, Whole mAb, Anti-CSF1R Antibody: Anti-FMS/CSFR/FIM2/HDLS/C-FMS/CD115/HDLS1/CSF-1R/BANDDOS/M-CSF-R therapeutic antibody |
| INN Name | Cabiralizumab |
| Target | CSF1R |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Apexigen;Bristol-Myers Squibb;Five Prime Therapeutics;University of Chicago;Yale University |
| Conditions Approved | na |
| Conditions Active | Pancreatic cancer;Pigmented villonodular synovitis;Cancer;Malignant melanoma;Non-small cell lung cancer;Renal cell carcinoma;Solid tumours |
| Conditions Discontinued | Rheumatoid arthritis |
| Development Tech | na |
